Literature DB >> 17610352

Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury.

Xiao Ru Chen1, Valerie C Besson, Bruno Palmier, Yannick Garcia, Michel Plotkine, Catherine Marchand-Leroux.   

Abstract

We previously demonstrated that fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, reduced the neurological deficit, the edema and the cerebral lesion induced by traumatic brain injury (TBI). In order to elucidate these beneficial effects, in the present study, we investigated, in the same TBI model, fenofibrate's effects on the inflammation and oxidative stress. Male Sprague Dawley rats were randomized in four groups: non-operated, sham-operated, TBI + vehicle, TBI + fenofibrate. TBI was induced by lateral fluid percussion of the temporoparietal cortex. Rats were given fenofibrate (50 mg/kg) or its vehicle (water containing 0.2% methylcellulose), p.o. 1 and 6 h after brain injury. A neurological assessment was done 24 h after TBI, then rats were killed and the brain COX2, MMP9 expression, GSx, GSSG levels were determined. The same schedule of treatment was used to evaluate the effect of fenofibrate on immunohistochemistry of 3NT, 4HNE and iNOS at 24 h post-injury. Our results showed that fenofibrate promotes neurological recovery by exerting anti-inflammatory effect evidenced by a decrease in iNOS, COX2 and MMP9 expression. In addition, fenofibrate showed anti-oxidant effect demonstrated by a reduction of markers of oxidative stress: loss of glutathione, glutathione oxidation ratio, 3NT and 4HNE staining. Our data suggest that PPARalpha activation could mediate pleiotropic effects and strengthen that it could be a promising therapeutic strategy for TBI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17610352     DOI: 10.1089/neu.2006.0216

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  49 in total

1.  The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice.

Authors:  Akshata Almad; A Todd Lash; Ping Wei; Amy E Lovett-Racke; Dana M McTigue
Journal:  Exp Neurol       Date:  2011-09-21       Impact factor: 5.330

Review 2.  Combination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better?

Authors:  Anthony E Kline; Jacob B Leary; Hannah L Radabaugh; Jeffrey P Cheng; Corina O Bondi
Journal:  Prog Neurobiol       Date:  2016-05-07       Impact factor: 11.685

3.  Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors.

Authors:  Bridgette D Semple; Linda J Noble-Haeusslein
Journal:  Exp Neurol       Date:  2011-02-21       Impact factor: 5.330

4.  Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery.

Authors:  Samir P Patel; David H Cox; Jenna L Gollihue; William M Bailey; Werner J Geldenhuys; John C Gensel; Patrick G Sullivan; Alexander G Rabchevsky
Journal:  Exp Neurol       Date:  2017-03-30       Impact factor: 5.330

Review 5.  A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis?

Authors:  Ruchira M Jha; Patrick M Kochanek
Journal:  Curr Neurol Neurosci Rep       Date:  2018-11-07       Impact factor: 5.081

Review 6.  Advances in the medical treatment of diabetic retinopathy.

Authors:  Rafael Simó; Cristina Hernández
Journal:  Diabetes Care       Date:  2009-08       Impact factor: 17.152

Review 7.  Pharmacology of traumatic brain injury: where is the "golden bullet"?

Authors:  Kathryn Beauchamp; Haitham Mutlak; Wade R Smith; Esther Shohami; Philip F Stahel
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

8.  Beneficial effects of fenofibrate in pulmonary hypertension in rats.

Authors:  Palak Galhotra; Pankaj Prabhakar; Himanshu Meghwani; Soheb A Mohammed; Sanjay Kumar Banerjee; Sandeep Seth; Milind P Hote; K H Reeta; Ruma Ray; Subir Kumar Maulik
Journal:  Mol Cell Biochem       Date:  2018-05-14       Impact factor: 3.396

Review 9.  Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation.

Authors:  Valerie C Besson
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

10.  Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Meri Gerges; Natalia Starkova; Noel Y Calingasan; Lichuan Yang; Davide Tampellini; Anatoly A Starkov; Robin B Chan; Gilbert Di Paolo; Aurora Pujol; M Flint Beal
Journal:  Hum Mol Genet       Date:  2012-08-24       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.